Alzheimer disease trials in Croatia
9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Grad Zagreb, Rijeka, Split, Varazdin, Zagreb
- Age
- 55 years to 90 years
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732EU 2025-520613-31-00Registry updated 2026-11-06
Phase 2RecruitingTrial-stage medicine
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Zagreb
- Age
- 55 years and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833Registry updated 2026-11-03
Phase 2RecruitingTrial-stage medicine
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Where
- Grad Zagreb, Zagreb
- Age
- 55 years and over
- People
- 320 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06651567EU 2024-514680-26-00Registry updated 2026-11-03
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Grad Zagreb, Zagreb
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787EU 2024-516363-92-00Registry updated 2026-10-27
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Grad Zagreb, Osijek, Rijeka
- Age
- 60 years to 85 years
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216EU 2025-520746-30-00Registry updated 2026-10-27
Phase 3RecruitingTrial-stage medicine
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Grad Zagreb
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949EU 2023-504151-27-00Registry updated 2026-10-16
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Grad Zagreb, Rijeka, Split, Varazdin, Zagreb
- Age
- 55 years to 90 years
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229EU 2024-519994-20-00Registry updated 2026-10-16
Phase 2RecruitingResearch participation
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
- Where
- Grad Zagreb
- Age
- 18 years and over
- People
- 216 worldwide
- Run by
- Intra-Cellular Therapies Inc.
See details and how to join2024-513035-25-00EU 2024-513035-25-00Registry updated 2026-08-20
Phase 3RecruitingTrial-stage medicine
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Where
- Zagreb
- Age
- 55 years to 90 years
- People
- 410 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363Registry updated 2026-08-17
All Alzheimer disease trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.